LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Inicio・Lista de Acciones・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Cerrado

SectorSanidad

19.39 -3.72

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

19.3

Máximo

20.36

Métricas clave
By Trading Economics
Ingresos	25M -43M
Ventas	-3.6M 65M
BPA	-0.48
Margen de beneficios	-65.788
Empleados	298
EBITDA	-16M -31M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+97.28% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	42M 1.9B
Apertura anterior	23.11
Cierre anterior	19.39

Noticias sobre sentimiento de mercado

By Acuity

100%

320 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

9.91 / 14.15 Soporte y Resistencia

Syndax Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 may 2026, 23:53 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 may 2026, 22:47 UTC

Acciones populares

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 may 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 may 2026, 22:00 UTC

Principales Movimientos del Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 may 2026, 18:09 UTC

Principales Movimientos del Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 may 2026, 23:50 UTC

Charlas de Mercado

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 may 2026, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 may 2026, 23:36 UTC

Charlas de Mercado

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 may 2026, 23:07 UTC

Adquisiciones, fusiones, absorciones

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

UOB: Share Sale Agreements Entered With Singland Properties

17 may 2026, 23:05 UTC

Adquisiciones, fusiones, absorciones

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Acquire Stake for $389 Million

17 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 may 2026, 16:27 UTC

Adquisiciones, fusiones, absorciones

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 may 2026, 15:26 UTC

Adquisiciones, fusiones, absorciones

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 may 2026, 08:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 may 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 may 2026, 21:16 UTC

Charlas de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 20:19 UTC

Acciones populares

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 may 2026, 19:41 UTC

Adquisiciones, fusiones, absorciones

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 may 2026, 19:35 UTC

Charlas de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 may 2026, 18:35 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparación entre iguales

Cambio de precio

Syndax Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

97.28% repunte

Estimación a 12 Meses

Media 39.91 USD 97.28%

Máximo 57 USD

Mínimo 29 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

9.91 / 14.15Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

320 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.